ANAPTYSBIO, INC ANAB

Rank #2387 · Nasdaq · $1.4B market cap

Audited by KPMG LLP, no going-concern flag in the latest filing.

Score

21.1

P/E

-8.6

P/B

5.36

ROE

-62.4%

Op. Margin

-958.3%

Debt Ratio

85%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Weak

P/E -8.6x, P/B 5.36x. Ranks in the top 76% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -62.4%. Ranks in the top 93% of the universe.

Safety ★★★☆☆

Good

Debt ratio 85%. Ranks in the top 34% of the universe.

Growth ★★★★★

Excellent

Revenue growth of 66.8% year over year. Ranks in the top 6% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2017	–	$-0.0B	$-0.0B	$-0.0B	–	-302
2018	$0.0B	$-0.0B	$-0.0B	$-0.0B	-18.1	-1036
2019	$0.0B	$-0.0B	$-0.0B	$-0.0B	-287.8	-1431
2020	$0.0B	$-0.1B	$-0.1B	$0.3B	-1334.4	41
2021	$0.0B	$-0.1B	$-0.1B	$0.5B	-1342.9	-14
2022	$0.1B	$-0.0B	$-0.0B	$0.4B	-31.8	59
2023	$0.1B	$-0.1B	$-0.1B	$0.4B	-89.9	54
2024	$0.0B	$-0.1B	$-0.1B	$0.4B	-1119.4	27
2025	$0.0B	$-0.2B	$-0.2B	$0.3B	-958.3	85